Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

TMDX DEADLINE FOR LEADERSHIP is April 15, 2025 in a Securities Fraud Lawsuit Contact Kaplan Fox

Mar 28, 2025 (NewMediaWire via COMTEX) --
NEW YORK - March 28, 2025 (NEWMEDIAWIRE) -Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) on behalf of investors that purchased or otherwise acquired TransMedics securities between February 28, 2023 and January 10, 2025 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in TransMedics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 15, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, on January 10, 2025, Scorpion Capital issued a report regarding TransMedics (“the Report”). The Report alleges, among other things, fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The Report also alleges that the Company may be under regulatory scrutiny by the U.S. Department of Justice, Internal Revenue Service, and state attorneys general for Medicare fraud linked to organ acquisition costs.

On January 10, 2024, the price of TransMedics stock fell $3.74 per share, over 5%, to close at $68.81 per share. The stock continued to decline the following day, dropping nearly 7% to close at $64.05 on January 13, 2025.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (ii) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (iii) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York10022
(646) 315-9003
pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/transmedics-group-inc/

View the original release on www.newmediawire.com

comtex tracking

COMTEX_464030696/2549/2025-03-28T13:34:14

Do not sell my personal information

Copyright © 2025. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.